Computer-Assisted Drug Design group invites applications for PhD position under the guidance of Prof. Gisbert Schneider.
ETH Zurich is one of the leading international universities for technology and the natural sciences. It is well known for its excellent education, ground-breaking fundamental research and for implementing its results directly into practice.
The aim of the project is to apply and develop Ligand and Receptor based molecular design methods and machine learning algorithms for small molecule design in drug discovery. This PhD position is element of the Euopean Marie Skłodowska-Curie ITN project BigCHEM (Horizon 2020 MSC ITN EID project). The selected candidate will spend half of the time with the industrial partner.
Computer-Assisted Drug Design project, Tasks includes:
- Development and adaptation of chem.-informatics software tools.
- Compound library profiling, chemical database management, and de novo ligand design.
- Strong interactions with other PhD candidates and the willingness to work as a member of a team.
Qualifications and Requirements:
- The aspirant shall have a strong background in cheminformatics, bioinformatics programming and chemistry.
- Aspirant should possess sound knowledge of machine learning algorithms.
- Good programming skills in languages like Java and/or C, scripting languages and chem.-informatics programming toolkits is expected from the candidate
- Candidates should be self motivated, self organized, creative, displaying initiative and used to thinking sideways.
- Superb command of the English language is expected.
- Candidates must be ready to travel and work for most of their time in the pharmaceutical industry.
Application Procedure: Applications must contain the following
- Statement of research interest
- Curriculum Vitae
- Names of references (Two)
- Copies of degree certificates.
Note: Only online applications are accepted through http://bigchem.eu/node/48
|Subject areas||Computer Science, Bioinformatics, Chemistry|
|Eligibility||Degree in relevant subject|
|Deadline||30 June 2016|
For Further Details:
Prof. Dr. Gisbert Schneider